Table 1.
Baseline characteristics of the study participants, according to treatment group (warfarin versus aspirin). For continuous variables, mean ± SD were reported, and p-values were calculated using two-sample t-test. For categorical variables, number /total number (%) were reported, and p-values were calculated using Chi-squared test.
| Characteristic | Warfarin (n=1101) | Aspirin (n=1123) | p-value |
|---|---|---|---|
| Age - years | 60.9± 11.5 | 60.7±11.1 | 0.647 |
| Male sex | 879/1101 (79.8) | 910/1123 (81.0) | 0.477 |
| Race or ethnic group | 0.862 | ||
| Non-Hispanic white | 830/1101 (75.4) | 856/1123 (76.2) | . |
| Non-Hispanic black | 158/1101 (14.4) | 153/1123 (13.6) | . |
| Hispanic | 83/1101 (7.5) | 79/1123 (7.0) | . |
| Other | 30/1101 (2.7) | 35/1123 (3.1) | . |
| Body-mass index – kg / m2 | 28.9± 5.9 | 29.2± 6.0 | 0.197 |
| Systolic blood pressure - mmHg | 124.0±19.4 | 124.2±18.4 | 0.832 |
| Diastolic blood pressure - mmHg | 74.1±11.6 | 74.5±11.3 | 0.402 |
| Pulse - beats/min | 71.8±11.3 | 72.1±12.5 | 0.479 |
| Hypertension | 669/1101 (60.8) | 692/1123 (61.6) | 0.678 |
| Diabetes Mellitus | 359/1101 (32.6) | 337/1123 (30.0) | 0.187 |
| Atrial Fibrillation | 42/1101 (3.8) | 38/1123 (3.4) | 0.585 |
| Peripheral Vascular Disease | 130/1101 (11.8) | 122/1123 (10.9) | 0.483 |
| Prior stroke or TIA | 148/1101 (13.4) | 137/1123 (12.2) | 0.381 |
| Ischemic Cardiomyopathy | 475/1101 (43.1) | 488/1123 (43.5) | 0.882 |
| Smoking status | 0.424 | ||
| Current smoker | 211/1099 (19.2) | 193/1122 (17.2) | . |
| Former smoker | 563/1099 (51.2) | 579/1122 (51.6) | . |
| Never smoked | 325/1099 (29.6) | 350/1122 (31.2) | . |
| NYHA classification | 0.502 | ||
| 1 | 145/1098 (13.2) | 160/1118 (14.3) | . |
| 2 | 595/1098 (54.2) | 626/1118 (56.0) | . |
| 3 | 343/1098 (31.2) | 319/1118 (28.5) | . |
| 4 | 15/1098 (1.4) | 13/1118 (1.2) | . |
| Ejection fraction - % | 24.6± 7.5 | 24.9± 7.5 | 0.319 |